Skye Bioscience (SKYE)

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

The Skye Bioscience, Inc. Common Stock (SKYE) stock price today is $0.78, reflecting a +0.93% move since the market opened. The company’s market capitalization stands at $25.09M, with a daily trading volume of $142.02K shares. For investors tracking price trends, Skye Bioscience, Inc. Common Stock stock has ranged between $0.74 and $0.79 today. The previous closing price was $0.78.

Ready to get started? Follow the steps below, or read our guide on how to buy Skye Bioscience stock on Kraken starting from $10.